Impact of adalimumab on rheumatoid arthritis (RA) outcomes: Comparison of an open-label extension study and a registry-based control group

被引：0
|
作者：
Halpern, M. T. [1 ]
Citaldi, M. [2 ]
Kvien, T. [3 ]
机构：
[1] Emory Univ, Dept Hlth Policy & Management, Atlanta, GA 30322 USA
[2] Abbott Labs, Global Hlth Econ & Outcomes Res, Abbott Pk, IL 60064 USA
[3] Diakonjemmet Hosp, Dept Rheumatol, Oslo, Norway
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2007年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：171 / 171
页数：1
相关论文
共 50 条
  • [21] Long-Term Safety and Efficacy of Olokizumab in Patients with Rheumatoid Arthritis - Results of an Open-Label Extension Study
    Feist, Eugen
    Nasonov, Evgeny
    Luggen, Michael
    Fatenejad, Saeed
    Grishin, Sergey
    Samsonov, Mikhail
    Fleischmann, Roy
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 603 - 606
  • [22] Safety and Efficacy of Baricitinib Through 128 Weeks in an Open-label, Longterm Extension Study in Patients with Rheumatoid Arthritis
    Keystone, Edward C.
    Genovese, Mark C.
    Schlichting, Douglas E.
    de la Torre, Inmaculada
    Beattie, Scott D.
    Rooney, Terence P.
    Taylor, Peter C.
    JOURNAL OF RHEUMATOLOGY, 2018, 45 (01) : 14 - 21
  • [23] Multiple switching between the biosimilar adalimumab PF-06410293 and reference adalimumab in patients with active rheumatoid arthritis: a phase 3, open-label, randomised, parallel-group study
    Fleischmann, Roy M.
    Saikali, Wassim
    Lakhanpal, Sharad
    Alvarez, Daniel F.
    Cox, Donna S.
    Ianos, Claudia Ana
    Zhang, Wuyan
    Cronenberger, Carol
    Wang, Karen
    LANCET RHEUMATOLOGY, 2023, 5 (09): : 532 - 541
  • [24] Outcomes of coronavirus disease 19 patients with a history of rheumatoid arthritis: A retrospective registry-based study in Iran
    Zargaran, Mahsa
    Movassaghi, Shafieh
    Seyyedsalehi, Monireh Sadat
    Zendehdel, Kazem
    Rostamian, Abdolrahman
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2022, 25 (10) : 1196 - 1199
  • [25] An open-label extension study of tocilizumab, in combination with disease modifying anti-rheumatic drugs, in patients with Rheumatoid Arthritis
    Hansrajh, V
    Rudolph, R.
    Tikly, M.
    Musenge, E.
    CLINICAL RHEUMATOLOGY, 2013, 32 : S146 - S146
  • [26] An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis
    Cohen, Stanley
    Pablos, Jose L.
    Pavelka, Karel
    Mueller, Gerard Anton
    Matsumoto, Alan
    Kivitz, Alan
    Wang, Hui
    Krishnan, Eswar
    ARTHRITIS RESEARCH & THERAPY, 2019, 21 (1)
  • [27] Combination treatment of severe rheumatoid arthritis with cyclosporine and methotrexate for forty-eight weeks - An open-label extension study
    Stein, CM
    Pincus, T
    Yocum, D
    Tugwell, P
    Wells, G
    Gluck, O
    Kraag, G
    Torley, H
    Tesser, J
    McKendry, R
    Brooks, RH
    ARTHRITIS AND RHEUMATISM, 1997, 40 (10): : 1843 - 1851
  • [28] An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis
    Stanley Cohen
    Jose L. Pablos
    Karel Pavelka
    Gerard Anton Müller
    Alan Matsumoto
    Alan Kivitz
    Hui Wang
    Eswar Krishnan
    Arthritis Research & Therapy, 21
  • [29] COMPARISON OF DISEASE STATUS AND OUTCOMES OF PATIENTS WITH RHEUMATOID ARTHRITIS (RA) RECEIVING ADALIMUMAB OR ETANERCEPT MONOTHERAPY IN EUROPE
    Narayanan, S.
    Lu, Y.
    Hutchings, R.
    Baynton, E.
    Hautamaki, E.
    VALUE IN HEALTH, 2014, 17 (07) : 374 - 374
  • [30] A multicentre, randomised, controlled, open-label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission
    Chatzidionysiou, Katerina
    Turesson, Carl
    Teleman, Annika
    Knight, Ann
    Lindqvist, Elisabet
    Larsson, Per
    Coster, Lars
    Forslind, Kristina
    van Vollenhoven, Ronald
    Heimburger, Mikael
    RMD OPEN, 2016, 2 (01):
12345